资料显示，南京麦澜德医疗科技股份有限公司位于江苏省南京市雨花台区凤展路32号A2栋，成立日期 2013年1月16日，上市日期2022年8月11日，公司主营业务涉及从事盆底及产后康复领域相关产品的研 发、生产、销售和服务。主营业务收入构成为：盆底康复产品36.98%，生殖康复产品33.10%，耗材及 配件24.32%，运动康复产品2.77%，其他(补充)2.18%，其他产品0.66%。 截至6月30日，麦澜德股东户数5461.00，较上期增加10.84%；人均流通股6743股，较上期减少9.78%。 2025年1月-6月，麦澜德实现营业收入2.41亿元，同比增长5.62%；归母净利润6392.01万元，同比减少 11.96%。 10月10日，麦澜德跌1.78%，成交额6179.31万元。两融数据显示，当日麦澜德获融资买入额914.28万 元，融资偿还1099.95万元，融资净买入-185.67万元。截至10月10日，麦澜德融资融券余额合计1.33亿 元。 分红方面，麦澜德A股上市后累计派现2.68亿元。 融资方面，麦澜德当日融资买入914.28万元。当前融资余额1.33亿元，占流通市值的8.83%，融资余额 超 ...

Core Viewpoint - 麦澜德's stock price has shown significant volatility, with a year-to-date increase of 77.07%, but recent declines in the short term raise questions about future performance [2][3]. Company Overview - 南京麦澜德医疗科技股份有限公司, established on January 16, 2013, and listed on August 11, 2022, specializes in the research, production, sales, and services of products related to pelvic floor and postpartum rehabilitation [2]. - The company's revenue composition includes pelvic rehabilitation products (36.98%), reproductive rehabilitation products (33.10%), consumables and accessories (24.32%), sports rehabilitation products (2.77%), and other products (2.84%) [2]. Financial Performance - For the first half of 2025, 麦澜德 reported revenue of 241 million yuan, a year-on-year increase of 5.62%, while net profit attributable to shareholders decreased by 11.96% to 63.92 million yuan [3]. - Since its A-share listing, 麦澜德 has distributed a total of 268 million yuan in dividends [4]. Shareholder and Market Activity - As of June 30, 2025, 麦澜德 had 5,461 shareholders, an increase of 10.84% from the previous period, with an average of 6,743 circulating shares per shareholder, down by 9.78% [3]. - The stock has experienced significant trading activity, with a recent net outflow of 1.528 million yuan in principal funds, indicating mixed investor sentiment [1][2].

Company Overview - Nanjing Mailland Medical Technology Co., Ltd. was established on January 16, 2013, and went public on August 11, 2022. The company is located in Nanjing, Jiangsu Province, and specializes in the research, development, production, sales, and services related to pelvic floor and postpartum rehabilitation products [1]. Business Segmentation - The main business revenue composition is as follows: pelvic rehabilitation products account for 36.98%, reproductive rehabilitation products 33.10%, consumables and accessories 24.32%, sports rehabilitation products 2.77%, other supplementary products 2.18%, and other products 0.66% [1]. Stock Performance - On September 16, Mailland's stock rose by 5.04%, reaching a price of 41.87 CNY per share, with a trading volume of 59.33 million CNY and a turnover rate of 3.97%. The total market capitalization is 4.187 billion CNY [1]. Shareholder Information - Among the top ten circulating shareholders of Mailland, a fund under Huatai-PineBridge holds a position. The Huatai Growth Focus Mixed Fund (519068) reduced its holdings by 299,400 shares in the second quarter, now holding 363,800 shares, which represents 0.99% of the circulating shares. The estimated floating profit today is approximately 731,200 CNY [2]. Fund Performance - The Huatai Growth Focus Mixed Fund (519068) was established on March 12, 2007, with a current asset size of 2.851 billion CNY. Year-to-date returns are 18.31%, ranking 4,518 out of 8,174 in its category; the one-year return is 29.39%, ranking 5,272 out of 7,982; and since inception, the return is 355.46% [2]. Fund Management - The fund manager of Huatai Growth Focus Mixed Fund is Chen Xiaoyang, who has been in the position for 3 years and 261 days. The best fund return during his tenure is -33.12%, and the worst is also -33.12% [3].

8月28日，麦澜德跌1.51%，成交额1.51亿元。两融数据显示，当日麦澜德获融资买入额1469.10万元， 融资偿还2295.45万元，融资净买入-826.35万元。截至8月28日，麦澜德融资融券余额合计1.59亿元。 分红方面，麦澜德A股上市后累计派现2.68亿元。 机构持仓方面，截止2025年6月30日，麦澜德十大流通股东中，华夏稳增混合（519029）位居第三大流 通股东，持股125.21万股，相比上期增加14.17万股。中信建投轮换混合A（003822）位居第五大流通股 东，持股65.62万股，为新进股东。中信建投甄选混合A（008347）位居第七大流通股东，持股56.33万 股，为新进股东。汇添富成长焦点混合（519068）位居第十大流通股东，持股36.38万股，相比上期减 少29.94万股。汇添富医药保健混合（470006）、国泰医药健康股票A（009805）、融通健康产业灵活配 置混合A/B（000727）退出十大流通股东之列。 责任编辑：小浪快报 资料显示，南京麦澜德医疗科技股份有限公司位于江苏省南京市雨花台区凤展路32号A2栋，成立日期 2013年1月16日，上市日期2022年8月11日， ...

Financial Performance - The company reported a total revenue of 241 million yuan for the first half of 2025, an increase of 5.62% year-on-year [1] - The net profit attributable to shareholders was 63.92 million yuan, a decrease of 11.96% compared to the previous year [1] - The gross margin was 70.9%, down 2.87% year-on-year, while the net margin decreased by 19.66% to 26.7% [1] - Total expenses (selling, administrative, and financial) amounted to 73.48 million yuan, accounting for 30.46% of revenue, an increase of 9.33% year-on-year [1] Key Financial Ratios - The company's return on invested capital (ROIC) was 7.34% last year, indicating average capital returns [3] - The historical median ROIC since the company went public is 37.57%, with the lowest ROIC recorded in 2023 at 5.65% [3] - The company has a healthy cash asset position, indicating good debt repayment capability [3] Market Position and Fund Holdings - The company is primarily driven by marketing efforts, which require further analysis to understand the underlying dynamics [3] - Notably, a prominent fund manager, Zhuan Jiangwei from CITIC Jiantou Fund, has increased holdings in the company, ranking among the top fifty fund managers in 2024 [3] - The largest fund holding the company is Huaxia Stable Growth Mixed Fund, with a scale of 1.146 billion yuan and a recent net value of 3.246, reflecting a 92.71% increase over the past year [4] Business Insights - The company's pelvic floor rehabilitation business is primarily composed of an in-hospital market, which accounts for over 85% of its customer base [5] - The out-of-hospital market has seen a decline in business share due to fertility rates, but the overall business volume has stabilized in recent years [5]